Tumor abnormality-oriented nanomedicine design
Anticancer nanomedicines have been proven effective in mitigating the side effects of
chemotherapeutic drugs. However, challenges remain in augmenting their therapeutic …
chemotherapeutic drugs. However, challenges remain in augmenting their therapeutic …
Current use of PSMA–PET in prostate cancer management
T Maurer, M Eiber, M Schwaiger… - Nature Reviews …, 2016 - nature.com
Currently, the findings of imaging procedures used for detection or staging of prostate
cancer depend on morphology of lymph nodes or bone metabolism and do not always meet …
cancer depend on morphology of lymph nodes or bone metabolism and do not always meet …
Diagnostic Efficacy of 68Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients …
T Maurer, JE Gschwend, I Rauscher… - The Journal of …, 2016 - auajournals.org
Purpose: Current standard imaging techniques are insufficient to reliably detect lymph node
metastases in prostate cancer. Recently ligands of PSMA (prostate specific membrane …
metastases in prostate cancer. Recently ligands of PSMA (prostate specific membrane …
Simultaneous 68Ga-PSMA HBED-CC PET/MRI improves the localization of primary prostate cancer
M Eiber, G Weirich, K Holzapfel, M Souvatzoglou… - European urology, 2016 - Elsevier
Background Ligands of the prostate-specific membrane antigen (PSMA) show promising
results in positron emission tomography (PET) imaging of prostate cancer (PCa). Objective …
results in positron emission tomography (PET) imaging of prostate cancer (PCa). Objective …
The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor …
A Afshar-Oromieh, H Hetzheim… - Journal of Nuclear …, 2015 - Soc Nuclear Med
PET imaging with the prostate-specific membrane antigen (PSMA)–targeted radioligand
68Ga-PSMA-11 is regarded as a significant step forward in the diagnosis of prostate cancer …
68Ga-PSMA-11 is regarded as a significant step forward in the diagnosis of prostate cancer …
[HTML][HTML] 68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/computed tomography for prostate cancer: a systematic review and …
Context 68 Gallium prostate-specific membrane antigen (PSMA) ligand 68 Ga-HBED-CC-
PSMA (68 Ga-PSMA) is a promising radiotracer for positron emission tomography …
PSMA (68 Ga-PSMA) is a promising radiotracer for positron emission tomography …
Prostate-specific membrane antigen ligands for imaging and therapy
The prostate-specific membrane antigen (PSMA) is highly expressed on most prostate
cancer (PC) cells. Therefore, the targeting of PSMA has become increasingly important over …
cancer (PC) cells. Therefore, the targeting of PSMA has become increasingly important over …
PET/CT with 11C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data
S Fanti, S Minozzi, P Castellucci, S Balduzzi… - European journal of …, 2016 - Springer
Purpose For the last decade PET and PET/CT with 11 C-choline have been proposed for the
evaluation of prostate cancer (PC), but the diagnostic performance of 11 C-choline PET/CT …
evaluation of prostate cancer (PC), but the diagnostic performance of 11 C-choline PET/CT …
Peptide-based nanoprobes for molecular imaging and disease diagnostics
P Zhang, Y Cui, CF Anderson, C Zhang, Y Li… - Chemical Society …, 2018 - pubs.rsc.org
Pathological changes in a diseased site are often accompanied by abnormal activities of
various biomolecules in and around the involved cells. Identifying the location and …
various biomolecules in and around the involved cells. Identifying the location and …
[PDF][PDF] Theranostic pretargeting drug delivery and imaging platforms in cancer precision medicine
S Hapuarachchige, D Artemov - Frontiers in oncology, 2020 - frontiersin.org
Theranostics are nano-size or molecular-level agents serving for both diagnosis and
therapy. Structurally, they are drug delivery systems integrated with molecular or targeted …
therapy. Structurally, they are drug delivery systems integrated with molecular or targeted …